Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Net Cash Flow (2021 - 2025)

Prime Medicine (PRME) has disclosed Net Cash Flow for 5 consecutive years, with -$8.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 112.97% year-over-year to -$8.4 million, compared with a TTM value of -$119.8 million through Dec 2025, down 184.69%, and an annual FY2025 reading of -$119.8 million, down 184.69% over the prior year.
  • Net Cash Flow was -$8.4 million for Q4 2025 at Prime Medicine, down from $17.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $139.7 million in Q4 2022 and bottomed at -$90.6 million in Q1 2025.
  • Average Net Cash Flow over 5 years is -$7.3 million, with a median of -$12.9 million recorded in 2023.
  • The sharpest move saw Net Cash Flow skyrocketed 6691.46% in 2022, then plummeted 272.28% in 2025.
  • Year by year, Net Cash Flow stood at -$2.1 million in 2021, then surged by 6691.46% to $139.7 million in 2022, then plummeted by 101.71% to -$2.4 million in 2023, then soared by 2804.36% to $64.5 million in 2024, then crashed by 112.97% to -$8.4 million in 2025.
  • Business Quant data shows Net Cash Flow for PRME at -$8.4 million in Q4 2025, $17.6 million in Q3 2025, and -$38.4 million in Q2 2025.